Repligen Corp
RGEN· Nasdaq
RGENRepligen Corp
Filed Feb 22, 2024 · 10-K · 53 days after period end · 0000950170-24-018809
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 |
|---|---|---|---|---|
| Revenue | $166.62M | $186.76M | $186.52M | $108.65M |
| Net Income | -$16.45M | $48.73M | $29.11M | $19.70M |
| EPS Diluted | — | — |
Repligen Corp · CIK 730272 · Engraved from SEC EDGAR
| — |
| $0.36 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2023 · filed Feb 22, 2024 · 53 d after period end
